Stools that are greasy, pale/clay coloured, or float (indicating fat malabsorption)
Research-only notice: This content is provided for educational discussion and laboratory research purposes only
or Appears on the 503A bulks list or 503A Category 1 Bulk Drug Substances Under Evaluation list (i.e., the interim 503A bulks list) provided by the FDA if requirements one or two are not met *note that the FDAs position is that specifically refers to USP/NF drug monographs, not dietary supplement monographs 503B outsourcing facilities are even further restricted in their allowed bulk materials and may not compound a drug product unless the relevant bulk drug product, in addition to being accompanied by a valid CoA and manufactured in an FDA registered facility, meets one of the below requirements: Appears on the list identifying bulk drug substances for which there is a clinical need (503B bulks list or 503B Category1: Bulk Drug Substances Under Evaluation (i.e., the interim 503B bulks list)
FDA-approved oligonucleotide therapies in 2017
5h, quantification: Supplementary Fig
Learn more about chelation therapy candidacy in this guide
